31 related articles for article (PubMed ID: 17486109)
1. Leuprolide-Induced Hyperosmolar Hyperglycemic State in an Elderly Patient: A Case Report and Literature Review.
Saad E; Babkir A; Awadelkarim AM; Qureshi F
Cureus; 2022 Jul; 14(7):e26993. PubMed ID: 35865181
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09).
Langley RE; Cafferty FH; Alhasso AA; Rosen SD; Sundaram SK; Freeman SC; Pollock P; Jinks RC; Godsland IF; Kockelbergh R; Clarke NW; Kynaston HG; Parmar MK; Abel PD
Lancet Oncol; 2013 Apr; 14(4):306-16. PubMed ID: 23465742
[TBL] [Abstract][Full Text] [Related]
3. High glucose promotes pancreatic cancer cell proliferation via the induction of EGF expression and transactivation of EGFR.
Han L; Ma Q; Li J; Liu H; Li W; Ma G; Xu Q; Zhou S; Wu E
PLoS One; 2011; 6(11):e27074. PubMed ID: 22087246
[TBL] [Abstract][Full Text] [Related]
4. Significance of serum calcitonin gene-related peptide levels in prostate cancer patients receiving hormonal therapy.
Suzuki K; Kobayashi Y; Morita T
Urol Int; 2009; 82(3):291-5. PubMed ID: 19440016
[TBL] [Abstract][Full Text] [Related]
5. Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy.
D'Amico AV; Renshaw AA; Loffredo B; Chen MH
Cancer; 2007 Oct; 110(8):1723-8. PubMed ID: 17828774
[TBL] [Abstract][Full Text] [Related]
6. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
7. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
8. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
[TBL] [Abstract][Full Text] [Related]
9. Glucose intolerance during hormonal therapy for prostate cancer.
Suzuki K; Nukui A; Hara Y; Morita T
Prostate Cancer Prostatic Dis; 2007; 10(4):384-7. PubMed ID: 17486109
[TBL] [Abstract][Full Text] [Related]
10. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth.
Basaria S
J Androl; 2008; 29(5):534-9. PubMed ID: 18567642
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic evaluation of PSA recurrence and review of hormonal management after radical prostatectomy.
Van Poppel H; Joniau S; Van Cleynenbreugel B; Mottaghy FM; Oyen R
Prostate Cancer Prostatic Dis; 2009; 12(2):116-23. PubMed ID: 19238169
[TBL] [Abstract][Full Text] [Related]
12. Intra-prostatic androgen levels during various androgen-blockade regimens.
Nishiyama T
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):229-41. PubMed ID: 18471782
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
